BMS CCR2 22

High affinity, potent CCR2 antagonist CAS# 445479-97-0

BMS CCR2 22

Catalog No. BCC7572----Order now to get a substantial discount!

Product Name & Size Price Stock
BMS CCR2 22: 5mg $713 In Stock
BMS CCR2 22: 10mg Please Inquire In Stock
BMS CCR2 22: 20mg Please Inquire Please Inquire
BMS CCR2 22: 50mg Please Inquire Please Inquire
BMS CCR2 22: 100mg Please Inquire Please Inquire
BMS CCR2 22: 200mg Please Inquire Please Inquire
BMS CCR2 22: 500mg Please Inquire Please Inquire
BMS CCR2 22: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of BMS CCR2 22

Number of papers citing our products

Chemical structure

BMS CCR2 22

3D structure

Chemical Properties of BMS CCR2 22

Cas No. 445479-97-0 SDF Download SDF
PubChem ID 57350027 Appearance Powder
Formula C28H34F3N5O4S M.Wt 593.66
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 100 mM in DMSO and to 10 mM in ethanol
Chemical Name N-[2-[[(1R,2S)-2-[(4-methylsulfanylbenzoyl)amino]cyclohexyl]amino]-2-oxoethyl]-2-(propan-2-ylcarbamoylamino)-5-(trifluoromethyl)benzamide
SMILES CC(C)NC(=O)NC1=C(C=C(C=C1)C(F)(F)F)C(=O)NCC(=O)NC2CCCCC2NC(=O)C3=CC=C(C=C3)SC
Standard InChIKey IBPXYDUJQWENPM-PKTZIBPZSA-N
Standard InChI InChI=1S/C28H34F3N5O4S/c1-16(2)33-27(40)36-21-13-10-18(28(29,30)31)14-20(21)26(39)32-15-24(37)34-22-6-4-5-7-23(22)35-25(38)17-8-11-19(41-3)12-9-17/h8-14,16,22-23H,4-7,15H2,1-3H3,(H,32,39)(H,34,37)(H,35,38)(H2,33,36,40)/t22-,23+/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of BMS CCR2 22

DescriptionHigh affinity CCR2 chemokine receptor antagonist (IC50 = 5.1 nM). Displays potent functional antagonism, IC50 values are 1 and 18 nM for chemotaxis and antagonism of calcium flux respectively. Selective over CCR3.

BMS CCR2 22 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

BMS CCR2 22 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of BMS CCR2 22

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.6845 mL 8.4223 mL 16.8447 mL 33.6893 mL 42.1116 mL
5 mM 0.3369 mL 1.6845 mL 3.3689 mL 6.7379 mL 8.4223 mL
10 mM 0.1684 mL 0.8422 mL 1.6845 mL 3.3689 mL 4.2112 mL
50 mM 0.0337 mL 0.1684 mL 0.3369 mL 0.6738 mL 0.8422 mL
100 mM 0.0168 mL 0.0842 mL 0.1684 mL 0.3369 mL 0.4211 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on BMS CCR2 22

High-content analysis of CCR2 antagonists on human primary monocytes.[Pubmed:21540351]

J Biomol Screen. 2011 Aug;16(7):683-93.

The monocyte chemoattractant protein 1 (MCP-1)-driven activation of CC-type chemokine receptor 2 (CCR2) is one of the early key events to induce monocyte migration toward centers of inflammation. In this work, the authors analyzed MCP-1 internalization into primary human monocytes using partially automated liquid handling, automated fluorescence microscopic imaging, and a specific image analysis algorithm. A fluorophore-conjugated form of MCP-1 was rapidly endocytosed and retained by the monocytes. The CCR2 dependency of the MCP-1 internalization was demonstrated by the use of BMS CCR2 22, a CCR2-specific antagonist. The apparent inhibitory potencies of a series of small-molecule CCR2 antagonists were determined and compared in five assay formats, including the high-content analysis assay described in this work. Interestingly, some but not all antagonists showed markedly different inhibitory behaviors in the five readout systems, with an up to more than 100-fold difference between the highest and the lowest apparent inhibitory potencies. These findings raise the distinct possibility that some CCR2 antagonists are capable of discriminating between different functional states of the CCR2 receptor(s) and suggest strategies for the identification of functionally selective CCR2 antagonists with increased therapeutic advantage over nonselective antagonists.

CCR2 receptor ligands inhibit Cav3.2 T-type calcium channels.[Pubmed:19864434]

Mol Pharmacol. 2010 Feb;77(2):211-7.

Monocyte chemoattractant protein-1 (MCP-1) is a cytokine known to be involved in the recruitment of monocytes to sites of injury. MCP-1 activates the chemokine (C-C motif) receptor 2 (CCR2), a seven-transmembrane helix G protein-coupled receptor that has been implicated in inflammatory pain responses. Here we show that MCP-1 mediates activation of the CCR2 receptor and inhibits coexpressed N-type calcium channels in tsA-201 cells via a voltage-dependent pathway. Moreover, MCP-1 inhibits Ca(v)3.2 calcium channels, but not other members of the Cav3 calcium channel family, with nanomolar affinity. Unlike in N-type channels, this modulation does not require CCR2 receptor activation and seems to involve a direct action of the ligand on the channel. Whole-cell T-type calcium currents in acutely dissociated dorsal root ganglia neurons are effectively inhibited by MCP-1, consistent with the notion that these cells express Ca(v)3.2. The effects of MCP-1 were eliminated by heat denaturation. Furthermore, they were sensitive to the application of the divalent metal ion chelator diethylenetriaminepentaacetic acid, suggesting the possibility that metal ions may act as a cofactor. Finally, small organic CCR2 receptor antagonists inhibit Ca(v)3.2 and other members of the T-type channel family with micromolar affinity. Our findings provide novel avenues for the design of small organic inhibitors of T-type calcium channels for the treatment of pain and other T-type channel linked disorders.

Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists.[Pubmed:18232650]

J Med Chem. 2008 Feb 28;51(4):721-4.

We describe the design, synthesis, and evaluation of novel disubstituted cyclohexanes as potent CCR2 antagonists. Exploratory SAR studies led to the cis-disubstituted derivative 22, which displayed excellent binding affinity for CCR2 (binding IC50 = 5.1 nM) and potent functional antagonism (calcium flux IC50 = 18 nM and chemotaxis IC 50 = 1 nM). Site-directed mutagenesis studies with 22 suggest the compound is binding near the key receptor residue Glu291, however, 22 is not reliant on Glu291 for its binding affinity.

Description

BMS CCR2 22 is a potent, specific and high affinity CC-type chemokine receptor 2 (CCR2) antagonist with excellent binding affinity (binding IC50 of 5.1 nM) and potent functional antagonism (calcium flux IC50 of 18 nM and chemotaxis IC50 of 1 nM).

Keywords:

BMS CCR2 22,445479-97-0,Natural Products,Chemokine Receptors, buy BMS CCR2 22 , BMS CCR2 22 supplier , purchase BMS CCR2 22 , BMS CCR2 22 cost , BMS CCR2 22 manufacturer , order BMS CCR2 22 , high purity BMS CCR2 22

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: